Navigation Links
Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
Date:10/23/2008

ng those caused by MRSA, as well as community acquired pneumonia. Novexel's future clinical development with NXL103 is expected to focus on its potential to be used in hospitals as an oral agent for the treatment of infections caused by Gram positive organisms, including resistant pathogens such as MRSA. Currently, physicians have a very limited choice of anti-MRSA antibacterials when they wish to switch from intravenous (IV) to oral treatment, a key step prior to a patient being discharged from the hospital.

In the second quarter of 2008 sanofi-aventis elected not to exercise its option to develop and commercialise NXL103. Consequently, worldwide rights to the NXL103 programme are retained by Novexel.

Iain Buchanan, Novexel's CEO, commenting on the announcement said, "We are very pleased that the results from our first Phase II clinical trial with NXL103 are positive. The data from this trial confirm the efficacy of NXL103 in patients with mild to moderate CAP. Furthermore, the pre-clinical and clinical work that we have carried out to-date with NXL103 provides a compelling platform for Phase III development. We believe that with its potent activity against MRSA, NXL103 may offer physicians an important therapeutic option when they switch patients from IV to oral treatment prior to discharge from the hospital."

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel anti-bacterials designed to overcome the significant global problem of bacterial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $15bn in 2007 according to information derived from the IMS Midas(R) database.

Novexel currently has two novel antibacterials in Phase II clinical development. These are the in
'/>"/>

SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
2. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
3. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
4. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
5. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
6. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
7. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
8. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
9. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
10. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
11. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... product to receive formal designation as a "Promising Innovative ... Scheme" (EAMS) launched in the UK in April 2014. ... process for early access approval under the EAMS.  ...
(Date:9/16/2014)... CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... and restatement of its outstanding Series C-2, C-3, ... as well as the warrants issued in its ... remove anti-dilution, price reset and certain change of ...
(Date:9/16/2014)... 16, 2014 Imprimis Pharmaceuticals, Inc. (Nasdaq: ... delivering high quality and novel medicines to physicians and ... Officer Mark Baum will be a presenter ... Conference in New York City.  Mr. Baum will discuss ... campaign in ophthalmology. The presentation is scheduled for 10:40 ...
Breaking Medicine Technology:NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4
... Pharmaceuticals, Inc. (NYSE Amex: INO ), a ... against cancers and infectious diseases, announced today the publication ... Vaccines detailing potent immune responses in a preclinical ... targeting two antigens. While current prostate cancer therapies target ...
... Feb. 1, 2011 Anthera Pharmaceuticals, Inc. (Nasdaq: ... treat serious diseases associated with abnormal auto-immune responses and ... Thompson to its Board of Directors. Currently, Dr. Thompson ... founder and Managing Director of Strategicon Partners, an investment ...
Cached Medicine Technology:Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 2Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 3Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 4Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 5Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors 2
(Date:9/16/2014)... Keep that sexy decolletage as you age, and frame ... Face Whisperer Neck & Decollete Cream is made ... Sublime Beauty®. "It contains rich ingredients to care for the ... A special ingredient is Argireline, known as the natural botox, ... comes in an airless pump bottle, and is part of ...
(Date:9/16/2014)... Park City, UT (PRWEB) September 16, 2014 ... Health Benefits Solution, published new information on transitioning ... to Zane Benefits, with the Affordable Care Act ... sized businesses will be steering some or all ... comes as no surprise. With guaranteed issue plans, ...
(Date:9/16/2014)... (PRWEB) September 17, 2014 UWDress.com, the ... new elegant evening wear assortment online. Additionally, ... products. All people can access big discounts now, up ... company’s elegant evening gowns are charming; it has won ... Along with evening outfits, it is also providing big ...
(Date:9/16/2014)... a healthcare climate where the costs of treatment ... study has found that radiation oncologists are using ... with early-stage breast cancer. The findings are scheduled ... of the American Society for Radiation Oncology in ... Radiotherapy for Elderly Women: Response to a Randomized ...
(Date:9/16/2014)... Recently, iFitDress.com, one of the most famous dress ... shoulder evening gown collection. According to the company’s sales ... rates (up to 69% off) at present. Additionally, all the ... “I am a frequent caller of your site. I like ... I feel quite happy. All items are of good quality. ...
Breaking Medicine News(10 mins):Health News:15% Off Face Whisperer® Neck & Decollete Cream Now from Sublime Beauty; Care For This Delicate Skin That Shows Age Quickly 2Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2Health News:New Elegant Evening Wear Assortment Released By UWDress.com 2Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2
... 27 Aflac Incorporated,(NYSE: AFL ) announced today ... & Woods 2008 Insurance Conference. President and Chief Financial,Officer ... is,scheduled to make a presentation on September 3, 2008, ... Cloninger will discuss the,company,s outlook for the remainder of ...
... wages and benefits, HEMET, Calif., Aug. 27 The ... against the,board of directors of Valley Health System (VHS) for ... already voted to agree to., "I do this job ... said,Lisa Howell, a registered nurse at Menifee Valley Medical Center. ...
... HARRISBURG, Pa., Aug. 27 Believe it or not,women ... women,s oral,health needs change at different stages throughout their ... Association (PDA) offers a reminder that,understanding these evolving oral ... stage of life, is getting the oral health care ...
... help regain pre-pregnancy body, IRVINE, Calif., ... of post-baby body shaping solution VelaShape(TM),and other ... body,contouring, today reveals the results of the ... women,s desire to regain their,pre-pregnancy body. Syneron ...
... not all part of normal aging process , , WEDNESDAY, Aug. ... women who remain free of dementia will nonetheless undergo an ... years before their death, a new study reveals. , Verbal ... of this cognitive decline, which is not, the researchers stressed, ...
... women quit smoking during pregnancy to protect their unborn children from ... a few months of giving birth. , By shedding light ... that cigarette for good, a study by researchers at the University ... to help women quit and stay quit. , According to the ...
Cached Medicine News:Health News:Aflac Incorporated To Present at the Keefe, Bruyette & Woods 2008 Insurance Conference 2Health News:State Board Issues Complaint: VHS Board Should Have Signed Contract With Caregivers 2Health News:What You Need to Know About Women's Oral Health 2Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 2Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 3Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 4Health News:Mental Skills Can Decline Years Before Dying 2Health News:Mental Skills Can Decline Years Before Dying 3Health News:Newly-defined factors may prevent postpartum smoking relapse 2Health News:Newly-defined factors may prevent postpartum smoking relapse 3
Castroviejo "HM" Micro Needle Holder with Tungsten-Carbide Inserts, with catch. Serrated....
Curved with catch....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Medium weight bone cutter....
Medicine Products: